KASPER implementation. Those who do perceive a change are nearly equally di-
vided between an increase and decrease in dispensing. Overall, the majority of re-
spondents believe that KASPER is an effective tool to reduce drug abuse, diver-
sion, and doctor shopping. Further research is necessary to assess the full effec-
tiveness of FDMPs.

**PHP94**

**THE US ORPHAN DRUG LANDSCAPE: BEFORE AND AFTER EU ORPHAN DRUG LEGISLATION OF 2000**

Bachman EM, Kumar J, Zaidi Q

**Heron Evidence Development, LLC., Somerville, NJ, USA**

**OBJECTIVES:** To encourage the development of orphan drug (OD) products, the European Union (EU) approved OD legislation in 2000, mirroring the US legislation passed in 1983. For the first time in history, these products were recognized as different from other drug products on a global level. Given this new global incentive for OD development, an increased focus on developing these products was ex-
pected. The objective of this research is to evaluate the change in the rate of global OD development as measured by the rate of US Food & Drugs Administration (FDA) OD designations. **METHODS:** All history within the OD database from the FDA website was included. The OD status, designation date, and contact company fields were analyzed to evaluate the OD designation rate and location of developers (US or non-US categories). **RESULTS:** There was a sharp increase in the number of FDA OD designations after the year 2000, with the rate of OD designations increasing by 475% compared to the prior period. From 1983 until 2000, 516 products received an FDA OD designation and the average increase in OD designation was 2.5 per year. From 2001 through 2009, the number of designations was 1966 and average in-
crease in OD designation was 14.7 per year. After 2000, the proportion of OD des-
nignations from non-US countries increased until 2009 when nearly one-third of products with a new FDA OD designation were from non-US companies. **CONCLUSIONS:** The implementation of EU OD legislation may have contributed to a change in the number of FDA OD designations per year and the types of compa-

doing ODs for the US. With developing markets preparing OD legislation, these policy changes may further stimulate the growth of the OD industry around the world.

**PHP95**

**PRESCRIPTION MONITORING PROGRAM EFFECTIVENESS: PERCEPTIONS OF DRUG DIVERSION INVESTIGATORS**

Perin NR, Freeman T, Talbert J, Blumenschein K

**University of Kentucky College of Pharmacy, Lexington, KY, USA**

**OBJECTIVES:** Most states have implemented prescription drug monitoring pro-
grams (PDMPs) to reduce prescription controlled substance (CS) abuse and diver-
sion. Relative little is known, however, about their effectiveness in achieving 
these goals. The purpose of this project was to assess the perceived impact of the 
Kentucky All Schedule Prescription Electronic Reporting Program (KASPER) on CS abuse, diversion and doctor shopping. **METHODS:** All law enforcement officials in Kentucky with an active KASPER account (119) were surveyed via email. Three hundred forty (340) responses were received yielding a response rate of 30%. Re-
sponses were coded and descriptive analysis was conducted in STATA v11. **RESULTS:** Nearly all (99%) law enforcement officials indicated that they had uti-
lized a KASPER report in the past and, on average, request 3.8 reports per month for 
use in drug diversion investigations. When asked for their opinion on how KASPER 
has affected health care provider behavior, the majority (70%) believed that phar-
macists had not altered the stocking and dispensing of CS, however, respondents 
were split on their opinion of prescriber behavior. Nearly half (45%) thought pre-
scribers had altered their prescribing of CS. With respect to law enforcement use of KASPER reports as an investigative tool, 67% of respondents indicated that infor-
mation contained in the report confirmed their decision to proceed with an inves-
tigation while 14% stated that the report caused them to close or dismiss pursuit of 
an investigation. Most (93%) respondents believe KASPER is an effective tool for 
reducing abuse and diversion while 90% believe it is an effective tool to reduce 

drug abuse, diversion and doctor shopping. **CONCLUSIONS:** Law enforcement officials believe that KASPER reports are a valuable tool when conducting investigations. Overall, the vast ma-

**HEALTH CARE USE & POLICY STUDIES – Risk Sharing/Performance-Based Agreements**

**PHP96**

**EVALUATION OF VALUE DRIVERS IN THE ADOPTION OF WELLNESS PROGRAMS FOR CHRONIC DISEASES**

Cabo R1, Nanjundaiah B2, Amato G2

1Cf Healthcare, Chalfont St. Giles, Bucks, UK, 2Cf Healthcare, Waukesha, WI, USA, 3Bridgehead International Ltd, Weymouth, MA, USA

**OBJECTIVES:** A growing global concern is the substantial prevalence of avoidable chronic disease states, which account for more than 75% of US health care ex-

dpenditures (CDC, 2010). In response, the utilization of wellness programs by stake-
holder groups to address modifiable risk factors for chronic disease states has in-
ex
creased. However, the broad variation in perceived value drivers by stakeholders has influenced widespread wellness program adoption. This study was undertaken to iden-
tify and evaluate critical clinical and economic drivers of wellness technol-
ogy and program adoption. **METHODS:** A comprehensive review of wellness pro-
gram design, utilization, and adoption drivers was conducted. Subsequently, an in-depth interview program of US stakeholders including payers, clinicians, employ-

ers and wellness program providers was performed. The interviews were designed to evaluate stakeholder perceptions of value drivers and measurements of well-
ness program adoption. **RESULTS:** Our data suggest that effective drivers of wellness program adoption are measurable with defined clinical or economic benefit(s). Optimizing technology utilization, altering negative patient behaviors and incenting 

**PHP97**

**PERCEPTIONS ON PAYER-INDUSTRY PARTNERSHIPS IN INFLUENCE COUNTRIES**

Marimon G1, Lockwood C1, Kowal S2, Gallo P2

1Bridgehead, UK, 2HHS, Washington, DC, USA

**OBJECTIVES:** This study sought to understand the current use of payer-industry partnerships in key influence markets and to gain insight into regional perspec-
tives on the current and future use of payer-industry partnerships. **METHODS:** Primary research was conducted through 57, 30–60 minute interviews of key stake-
holders from industry and regulatory agencies across 9 major markets (EU 5, United States, Japan, Canada, and Australia). Interview questionnaires were designed to understand perceptions regarding current partnerships as well as awareness of emerging models. Primary data was complemented by reviews of published and gray literature, government and other relevant agency websites, and IHS propriety Healthcare and Pharmaceutical content. **RESULTS:** Two broad categories of partnerships were predominantly used across the countries examined – partner-
ships for reimbursement decision-making (e.g. risk-sharing agreements) and part-
nerships downstream of reimbursement (e.g. disease management programs). One key finding was the acceptance of payer-industry partnerships as a necessary prac-
tice as opposed to short term trend. According to interviewees, partnerships are increasingly becoming a necessity because of gaps in funding. Given such chal-

**THE FUTURE OF ALTERNATIVE PRICING/RISK-SHARING AGREEMENTS IN THE UNITED STATES**

Goldenberg D, Bachman EM

**Heron Evidence Development, LLC., Somerville, NJ, USA**

**OBJECTIVES:** Due to the rising cost of health care in the United States, payers have begun to place an increased emphasis on cost when evaluating new submis-
sions for formulary access. Our objective was to evaluate the US payer perception of alternative pricing/risk-sharing (AP/RS) agreements focusing on: 1) assessing the success of previously implemented AP/RS agreements in the United States, and 2) evaluating conceptual AP/RS structures with payers to assess preference of concepts. **METHODS:** An online survey was conducted capturing perceptions of a broad spectrum of US payers on AP/RS agreements (n=19). Following the sur-
v
ey, in-depth interviews (n=5) were conducted with US national and regional pay-
ers to gain additional insight. **RESULTS:** More than 90% of US payers were inter-
ested in AP/RS agreements. Payers believed that these types of agreements could be implemented for both their pharmacy (84% of payers) and medical (42% of payers) benefits. Over half the payers (52%) believed that AP/RS agreements should be considered for orphan diseases, 68% believed that they should be considered for other rare diseases, and 73% believed that they should be considered for chronic high cost diseases. Payers expressed concerns about previous AP/RS agree-
ments were not successful due to a lack of independent data reporting and an imbalance in risk-sharing. Payers (73%) showed a preference for “pay-for-performance” schemes that offered predictable cost outlays and mutually beneficial risk agreements with clearly-defined and independently-verified success markers. **CONCLUSIONS:** US payers are keenly aware of alternative pricing/risk-sharing agreements and foresee them playing a larger role in future US negotiations if clear cost and risk benchmarks are established.